NCT05240690尚未招募1 期
Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies：HCCSC AB04 Trial
Zhou Fuxiang1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2022年2月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Progression-free Survival(PFS)
研究概览
简要总结
To evaluate the safety of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.And to investigate the initial efficacy of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age over 18 years old, under 75 years old, men and women;
- •Subjects participated voluntarily, gave full informed consent, signed a written informed consent, with good compliance;
- •Hepatocytic carcinoma or biliary or pancreatic-derived adenocarcinoma was clearly diagnosed by histological or cytology pathology;
- •Recurrent hepatobiliary or pancreatic malignancies with unresectable advanced or metastatic, or postoperative adjuvant therapy (chemotherapy and / or radiation therapy) for 12 months, with a Child-Pugh score of 7;
- •With 1 measurable lesion, according to the RECIST v 1.1 criteria.Requirements: The selected target lesion has not previously received local treatment, or the selected target lesion was located in the previous local treatment area after passing the imaging examination and was determined as PD according to the RECIST v 1.1 criteria;
- •ECOG score of 0-1;
- •Expected survival is greater than 3 months;
- •Main organ function composite with the following requirements:
- •Absolute neutrophil count was 1.5*10^9 / L;
- •Platelet count was 75*10^9 / L;
- •Hemoglobin was at 90g / L;
- •Serum albumin at 30g / L;
- •Serum bilirubin 1.5 upper Range normal limit (ULN);
- •Altraverine aminotransferase (ALT), aspartate aminotransferase (AST) 2.5 upper normal range limit (ULN);
- •Serum creatinine (Cr) 1.5 Upper Limit of normal range (ULN) or Cr clearance of 40 mL/min;
- •The International standardized ratio (INR) 2 or Prothrombin Time (PT) exceeds the upper limit of the normal range for 6 seconds;
- •Urinary protein <2 + (if urine protein 2 +, 24 h (h), and 24h <1.0g can be enrolled).
- •9.If HBsAg (+) and / or HBcAb (+), HBV DNA must be <500IU / mL and during the study period, the original anti-HBV treatment continues throughout the study, or start entecavir or teenofavir.
- •10.There is no previous history of abdominal radiotherapy. If radiation has been performed, the complete target area scope and treatment plan are more than 2 weeks apart from the study immune cell transfusion of this project; 11.No history of organ transplantation; 12.Women of childbearing age performed a serum pregnancy test within 7 days before the initiation of treatment, and agreed to adopt a reliable and effective contraceptive method during the trial and within 60 days after the final administration of the test drug.For male subjects with a partner of women of childbearing age, consent was given to a reliable and effective approach to contraception during the trial and within 60 days after the final administration of the test medication.
排除标准
- •At the same time, there are serious medical diseases, including serious heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled infection, active digestive tract ulcer;
- •Patients with brain metastasis with clinical symptoms;
- •Suffering from other primary malignancies in the past 5 years (except skin BCC or squamous cell carcinoma, cervical carcinoma in situ that have been effectively controlled);
- •Patients with immunodeficiency or autoimmune diseases (e. g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, insulin-dependent diabetes, etc.).
- •Patients who participated in other clinical trials or clinical study treatment within the 3 months prior to this clinical study.
- •Patients treated with other cells within the last 6 months.
- •Patients with infection and fever who were not effectively controlled.
- •Patients with high allergies or a history of severe allergies.
- •Patients with an albumin allergy.
- •Patients after organ transplantation; patients with long-term use or who are using immunosuppressants.
- •Patients with severe other organ dysfunction.
- •Patients with organ bleeding, severe hypertension, and patients with a cardiac pacemaker.
- •Women during pregnancy or lactation; or women of childbearing age have positive blood pregnancy, women of childbearing age and their spouses are unwilling to take effective contraception during the clinical study and within 6 months of the end.
- •Patients who are not considered appropriate to participate in this clinical study (e. g., poor compliance, etc.).
结局指标
主要结局
Progression-free Survival(PFS)
时间窗: 24 months
PFS is defined as the time from enrollment to the first documented disea
次要结局
- objective response rate (ORR)(24 months)
- disease control rate (DCR)(24 months)
- overall survival (OS)(24 months)
研究者
Zhou Fuxiang
Professor
Zhongnan Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic StrokeIschemic StrokeBrain IschemiaStrokeNCT01673932China Spinal Cord Injury Network12
Unknown
1 期
Umbilical Cord Blood Mononuclear Cells Therapy in Liver CirrhosisLiver CirrhosisNCT01942915Hebei Medical University10
已完成
1 期
Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal CordSpinal Cord InjuriesNCT01046786China Spinal Cord Injury Network8
撤回
不适用
Allogeneic Umbilical Cord Blood Therapy for Chronic TBITraumatic Brain InjuryNCT01451528Bundang CHA Hospital
Unknown
1 期
Safety and Efficacy of Autologous Umbilical Cord Blood Mononuclear Cells Transfusion in NeonatesSafety IssuesEffect of DrugsNeonatal DeathNCT03053076Guangdong Women and Children Hospital200